Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- candesartan
- Gen-K (potassium chloride)
Interactions between your drugs
potassium chloride candesartan
Applies to: Gen-K (potassium chloride), candesartan
MONITOR CLOSELY: Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia. Inhibition of angiotensin II results in decreased aldosterone secretion, which in turn causes potassium retention. Life-threatening and fatal hyperkalemia can occur, especially when the combination is used in patients with risk factors such as renal impairment, diabetes, advanced age, severe or worsening heart failure, dehydration, and concomitant use of other agents that block the renin-angiotensin-aldosterone system or otherwise increase serum potassium levels.
MANAGEMENT: Caution and close monitoring are advised if angiotensin II receptor blockers (ARBs) must be used concurrently with potassium salts due to the risk of potentially life-threatening hyperkalemia. Some authorities advise against combining certain ARBs with potassium salts unless the anticipated benefits substantially outweigh the potential risks. The risk of hyperkalemia is increased in older patients, those with certain disease states (e.g., renal impairment, diabetes, severe or worsening heart failure, dehydration) or when ARBs are also combined with other agents that increase serum potassium (e.g., nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim). Should the benefits outweigh the risks for a particular patient, serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients and their caregivers should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia (e.g., nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat). Individual product labeling should be consulted for further guidance.
References
- Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J (1984) "Hyperkalemia in the elderly." Clin Chem, 30, p. 1409-12
- Lawson DH, O'Connor PC, Jick H (1982) "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol, 23, p. 21-5
- Lawson DH (1974) "Adverse reactions to potassium chloride." Q J Med, 43, p. 433-40
- (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
- (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals
- Obialo CI, Ofili EO, Mirza T (2002) "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol, 90, p. 663-5
- Jarman PR, Mather HM (2003) "Diabetes may be independent risk factor for hyperkalaemia." BMJ, 327, p. 812
- Perazella MA (2000) "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med, 109, p. 307-14
- Jarman PR, Kehely AM, Mather HM (1995) "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J, 71, p. 551-2
- Perazella MA, Mahnensmith RL (1997) "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med, 12, p. 646-56
- Large DM, Carr PH, Laing I, Davies M (1984) "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J, 60, p. 370-3
- (2021) "Product Information. Irbesartan (irbesartan)." Alembic Pharmaceuticals
- (2022) "Product Information. Avapro (irbesartan)." Sanofi-Aventis Canada Inc
- (2021) "Product Information. Aprovel (irbesartan)." Sanofi
- (2021) "Product Information. Valsartan (valsartan)." Alembic Pharmaceuticals
- (2023) "Product Information. Auro-Valsartan (valsartan)." Auro Pharma Inc
- (2023) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals UK Ltd
- (2020) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals Pty Ltd
- (2023) "Product Information. Telmisartan (telmisartan)." Alembic Pharmaceuticals
- (2023) "Product Information. Ach-Telmisartan (telmisartan)." Accord Healthcare Inc
- (2023) "Product Information. Micardis (telmisartan)." Boehringer Ingelheim Ltd
- (2022) "Product Information. Micardis (telmisartan)." Boehringer Ingelheim Pty Ltd
- (2022) "Product Information. Olmesartan Medoxomil (olmesartan)." ASCEND LABORATORIES S.P.A.
- (2022) "Product Information. Olmesartan Medoxomil (olmesartan)." Thornton & Ross Ltd
- (2022) "Product Information. IXIA (olmesartán)." MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG, S.A.
- (2024) "Product Information. Losartan Potassium (losartan)." Strides Pharma Inc.
- (2023) "Product Information. Auro-Losartan (losartan)." Auro Pharma Inc
- (2022) "Product Information. Cozaar (losartan)." Organon Pharma (UK) Ltd
- (2022) "Product Information. Eprosartan (eprosartan)." Amarox Ltd
- (2021) "Product Information. Candesartan Cilexetil (candesartan)." Alembic Pharmaceuticals
- (2022) "Product Information. Amias (candesartan)." Neon Healthcare Ltd
- (2022) "Product Information. Edarbi (azilsartan)." Takeda UK Ltd
- (2020) "Product Information. DIOVAN (valsartán)." NOVARTIS FARMA S.P.A.
- (2008) "Product Information. MICARDIS (telmisartán)." BOEHRINGER INGELHEIM ESPAÑA, S.A.
- (2022) "Product Information. IXIA (olmesartán)." MENARINI,S.A.
- (2022) "Product Information. COZAAR (losartán)." Organon Pharmaceuticals
- (2021) "Product Information. IRBESARTAN CINFA (irbesartán)." CINFA S.A.
- (2022) "Product Information. FUTURAN (eprosartán)." VIATRIS
- (2021) "Product Information. CANDESARTAN CINFA (candesartán)." CINFA S.A.
Drug and food interactions
candesartan food
Applies to: candesartan
GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.
MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.
References
- (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
- (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.